Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-04-28 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
国浩律师（杭州）事务所关于贝达药业股份有限公司2021年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 Annual General Meeting (AGM) of Betta Pharmaceuticals Co., Ltd. It details the convening, attendance, agenda, voting procedures, and results of the AGM. The document focuses on the legality and validity of the AGM process and voting outcomes, not on the financial performance or management reports. It is not the AGM presentation materials themselves but a legal opinion related to the AGM. Given the content and purpose, this document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting results and validates the AGM procedures.
2022-04-28 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2021 Annual General Meeting (AGM) resolutions of Betta Pharmaceuticals Co., Ltd. It details the voting results on various proposals including the 2021 board report, supervisory board report, financial report, annual report, profit distribution plan, remuneration, auditor appointment, and financing guarantees. The document includes attendance details, voting percentages, and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but reports the official voting results from the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5514 characters, which is sufficient for a detailed voting results announcement but not a full report. Hence, the classification is DVA with high confidence.
2022-04-28 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2021年度持续督导培训情况的报告
Regulatory Filings Classification · 95% confidence The document is a report from CITIC Securities regarding the 2021 continuous supervision training conducted for Betta Pharmaceuticals Co., Ltd. It details the training session's basic information, participants, content, and outcomes. The document is relatively short (758 characters) and focuses on regulatory compliance training rather than financial results, management changes, or shareholder votes. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content aligns with regulatory compliance and supervisory activities, which do not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature of the document as a regulatory compliance report related to supervision and training, and the absence of a more specific category, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory documents that do not fit other categories.
2022-04-26 Chinese
2022年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "贝达药业股份有限公司 2022 年第一季度报告全文" which translates to "Beta Pharma Co., Ltd. 2022 First Quarter Report Full Text." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2022. The document includes management's discussion of business performance, financial results, and operational highlights for the quarter. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2022
2022-04-26 Chinese
中信证券股份有限公司关于贝达药业股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from CITIC Securities regarding the use of temporarily idle raised funds by Betta Pharmaceuticals for cash management. It references regulatory rules about the management and use of raised funds, details the amount and purpose of the raised funds, and discusses the approval process including board, supervisory board, and independent directors' opinions. The document is a verification or audit opinion on the use of funds rather than a full financial report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a brief announcement or a presentation. It is a standalone audit or verification report related to compliance and fund usage, fitting the category of Audit Report / Information (AR). The document length is 4114 characters, which is relatively short but contains substantive content beyond a mere announcement, so it is not a Report Publication Announcement (RPA). FY 2022
2022-04-26 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2021年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2021 annual verification of the storage and use of raised funds by Betta Pharmaceuticals Co., Ltd. It includes extensive financial data on fundraising amounts, usage, balances, investment projects, changes in project funding, and compliance with regulatory requirements. The document references specific regulatory guidelines and includes auditor opinions and verification reports. It is not a brief announcement or a certification letter but a comprehensive report on fundraising usage and compliance for the fiscal year 2021. This matches the characteristics of an Audit Report / Information (AR), which covers audit results and applied accounting principles related to specific financial activities, here focusing on fundraising and its management. The document is not an Annual Report (10-K) or Interim Report (IR) as it focuses solely on fundraising usage and verification, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains substantive financial data and audit opinions. Therefore, the correct classification is AR with high confidence. FY 2021
2022-04-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.